Evidence map›Paper›PMID 36269762›Full record

ArticleAmerican journal of respiratory and critical care medicine2023

PAI-1 Drives Septation and Clinical Outcomes in Pleural Infection.

Andrey A Komissarov, Steven Idell

Abstract readEditorialComment
In one paragraph

Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. SERPINE1 in ARDS: an emerging regulator of inflammation-coagulation-fibrinolysis crosstalk.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Andrey A KomissarovSchool of Medicine University of Texas Health Science Center at Tyler Tyler, Texas.
Steven IdellSchool of Medicine University of Texas Health Science Center at Tyler Tyler, Texas.

Funding

Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyemaR01HL130402 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI FLOROVA, GALINA, IDELL, STEVEN · 2017 to 2024
$3.8M
Enhanced Delivery of Thrombolytic Carriers for EmpyemaR01HL152059 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KLEGERMAN, MELVIN E, KOMISSAROV, ANDREY · 2021 to 2024
$2.5M
Fibrinolytic Proteases, meso-mesenchymal transition and pleural remodelingR01HL130133 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI TUCKER, TORRY ALLE · 2017 to 2021
$1.8M
Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic InterventionsR33HL154103 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI FLOROVA, GALINA, IDELL, STEVEN · 2020 to 2021
$881k
NHLBI NIH HHS R01 HL130133NHLBI NIH HHS R01HL130133NHLBI NIH HHS R01 HL130402NHLBI NIH HHS R01 HL152059NHLBI NIH HHS R33 HL154103
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pleural DiseasesPleural EffusionExudates and TransudatesHumansPlasminogen Activator Inhibitor 1Plasminogen Activator Inhibitor 1

Identifiers

PMID36269762
PMCPMC10037477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.